Table 2.
Ongoing clinical studies with ICEs in solid tumors registered on ClinicalTrials.gov
| Identifier | Drug name | ICE design | Condition | Phase | Note | Status |
|---|---|---|---|---|---|---|
| NCT03927573 | GEM3PSCA | PSMAxCD3 | Solid tumors | I | Recruiting | |
| NCT04104607 | CC-1 | PSMAxCD3 | Prostate cancer | I | Recruiting | |
| NCT04496674 | CC-1 | PSMAxCD3 | Squamous NSCLC | I/II | Recruiting | |
| NCT03792841 | AMG160 | PSMAxCD3 | Prostate cancer | I | ± Pembrolizumab | Recruiting |
| NCT03983395 | ISB1302 | HER2xCD3 | Breast cancer | I/II | Recruiting | |
| NCT03406858 | - | HER2xCD3 | Prostate cancer | II | + Pembrolizumab | Recruiting |
| NCT03661424 | - | HER2xCD3 | Breast cancer | I | Recruiting | |
| NCT03272334 | - | HER2xCD3 | Breast cancer | I/II | + Pembrolizumab | Recruiting |
| NCT03330561 | PRS-343 | HER2x4-1BB | Solid tumors | I | Recruiting | |
| NCT03269526 | - | EGFRxCD3 | Pancreatic cancer | I/II | Recruiting | |
| NCT03344250 | - | EGFRxCD3 | Glioblastoma | I | + Temozolomide | Recruiting |
| NCT03296696 | AMG596 | EGFRvIIIxCD3 | Glioblastoma | I | Active, non-recruiting | |
| NCT04009460 | ES101 | PD-L1x4-1BB | Solid tumors | I | Recruiting | |
| NCT03922204 | MCLA-145 | PD-L1x4-1BB | Solid tumors | I | Recruiting | |
| NCT03809624 | INBRX-105 | PD-L1x4-1BB | Solid tumors | I | Recruiting | |
| NCT03484962 | - | MUC1xCD3 | Hepatocellular carcinoma | II | + Activated cytokines-induced killer cells | Recruiting |
| NCT03564340 | REGN4018 | MUC16xCD3 | Ovarian cancer | I/II | ± Cemiplimab | Recruiting |
| NCT04117958 | AMG199 | MUC17xCD3 | Gastric cancer | I | Recruiting | |
| NCT04260191 | AMG910 | CLDN18.2xCD3 | Gastric cancer | I | Recruiting | |
| NCT03319940 | AMG757 | DLL1xCD3 | SCLC | I | ± Pembrolizumab | Recruiting |
| NCT04221542 | AMG 509 | STEAP1xCD3 | Prostate cancer | I | Recruiting | |
| NCT03531632 | MGD007 | gpA33xCD3 | Colorectal cancer | I/II | + MGA012 | Active non recruiting |
| NCT03860207 | Hu3F8-BsAb | GD2xCD3 | Solid tumors | I/II | Recruiting | |
| NCT04424641 | GEN1044 | 5T4xCD3 | Solid tumors | I/II | Not yet recruiting | |
| NCT03411915 | XmAb18087 | SSTR2xCD3 | NET and GIST | I | Recruiting | |
| NCT04128423 | AMV564 | CD33xCD3 | Solid tumors | I | Recruiting |
EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumor; HER2, human epidermal growth factor receptor 2; ICE, immune cell engager; NET, neuroendocrine tumor; PD-L1, programmed death-ligand 1; PSMA, prostate-specific membrane antigen; SCLC, small cell lung cancer.